Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group
Axel Le Cesne(Institut Gustave Roussy), Jaap Verweij(Deutz (Germany)), A. van Oosterom(European Organisation for Research and Treatment of Cancer), Q. van Hoesel(Radboud University Nijmegen), Jürgen Frisch(University of Freiburg), H.J. Keizer(Radboud University Nijmegen), M. van Glabbeke(Institut Jules Bordet), T Türsz(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), D. Crowther(Radboud University Nijmegen), C. Hermans(European Organisation for Research and Treatment of Cancer), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Sjoerd Rodenhuis(The Netherlands Cancer Institute), Ian Judson(Erasmus Hospital)
Cited by 258
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Cremophor EL
|European Journal of Cancer|2001|1.6k